Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant
Biological PsychiatryPublished 3 April 2004
Mats Bergström, Richard Hargreaves, H. Donald Burns, Michael R. Goldberg, David Sciberras, Scott A. Reines
Citations198
SJR quartileQ1
SJR score4.68
SNIP2.24
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Positron emission tomography imaging with [(18)F]SPA-RQ allows brain NK( 1) receptor occupancy by aprepitant to be predicted from plasma drug concentrations and can be used to guide dose selection for clinical trials of NK(1) receptor antagonists in central therapeutic indications.
Abstract
Positron emission tomography imaging with [(18)F]SPA-RQ allows brain NK(1) receptor occupancy by aprepitant to be predicted from plasma drug concentrations and can be used to guide dose selection for clinical trials of NK(1) receptor antagonists in central therapeutic indications.
Keywords
Medicine
The human nervous system
1,481 Citations2004George Paxinos, K. Jürgen
ScienceDistinct Mechanism for Antidepressant Activity by Blockade of Central Substance P Receptors
1,077 Citations1998Mark S. Kramer, Neal R. Cutler +25 more
The localization of substance P in brain regions that coordinate stress responses and receive convergent monoaminergic innervation suggested that substance P antagonists might have psychotherapeutic properties was found to be correct.
Therapeutic Drug MonitoringPharmacologic Analysis of Drug Receptor Interaction
929 Citations1988Kenakin. T. Kenakin
Drug receptor/theory seven transmembrane receptor behaviour human recombinant receptor systems stimulus-response mechanisms drug response mechanisms diffusion and drug concentration in receptor compartments statistical assessment of biological significance from data affinity efficacy competitive antagonism allotopic, noncompetitive, and irreversible antagonism methods.
CancerAddition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomiting
566 Citations2003S. Poli-Bigelli, José Rodrigues-Pereira +8 more
The authors sought to evaluate further the efficacy and tolerability of aprepitant plus standard therapy in a large clinical trial.
New England Journal of MedicineReduction of Cisplatin-Induced Emesis by a Selective Neurokinin-1–Receptor Antagonist
371 Citations1999Rudolph M. Navari, Rick R. Reinhardt +10 more
The neurokinin-1-receptor antagonist L-754,030 prevents delayed emesis after treatment with cisplatin and combined with granisetron plus dexamethasone improves the prevention of acute emesis.
The LancetPresynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients
322 Citations1995Jarmo Hietala, J. Hietala +14 more
Alterations in striatal presynaptic dopamine function may constitute a part of disrupted neural circuits that predispose to schizophrenic psychosis.
Journal of Cerebral Blood Flow & MetabolismQuantification of Neuroreceptors in the Living Human Brain. I. Irreversible Binding of Ligands
278 Citations1986Dean F. Wong, Albert Gjedde +1 more
The only accurate approach used measured plasma concentrations to estimate transfer constants at steady state and yielded the absolute rate of binding k3, which is applicable to other irreversibly bound ligands.
European Journal of CancerDifferential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists
250 Citations2003Paul J. Hesketh, Simon Van Belle +7 more
The difference in the time course of emesis blockade observed with two different classes of receptor antagonists provides substantial evidence for involvement of separate pathophysiological mechanisms in chemotherapy-induced vomiting.
Journal of Clinical OncologyPrevention of Cisplatin-Induced Emesis by the Oral Neurokinin-1 Antagonist, MK-869, in Combination With Granisetron and Dexamethasone or With Dexamethasone Alone
221 Citations2001Daniel de Castro, José Rodrigues Pereira +10 more
Once daily oral administration of MK-869 was effective in reducing delayed emesis and nausea after high-dose cisplatin, however, the combination of the 5HT3 antagonist plus dexamethasone was numerically superior to MK- 869 plus DexamethAsone in reducing acute emesis.
CancerEstablishing the dose of the oral NK<sub>1</sub> antagonist aprepitant for the prevention of chemotherapy‐induced nausea and vomiting
216 Citations2003Sant P. Chawla, Steven M. Grunberg +9 more
The most appropriate dose regimen of oral aprepitant is defined to reduce chemotherapy‐induced nausea and vomiting when it is given with a 5‐hydroxytryptamine‐3 receptor antagonist and dexamethasone.
Brain ResearchSubstance P receptors: Localization by light microscopic autoradiography in rat brain using [3H]SP as the radioligand
216 Citations1984Patrick W. Mantyh, Stephen P. Hunt +1 more
Comparisons of the present data with SP peptide levels indicate that in some areas of the brain there is a rough correlation between peptide and receptor levels, however, in other brain areas there is little obvious correlation between the two.
Brain ResearchRegional distribution of Neuropeptide K and other tachykinins (Neurokinin A, Neurokinin B and substance P) in rat central nervous system
194 Citations1986Heii Arai, Piers C. Emson
Modified elution conditions to resolve NPK from NKB were introduced and the regional distributions of these tachykinins in the rat CNS were determined and suggested that regional specific translation or processing may exist.
PubMedImaging substance P receptors (NK1) in the living human brain using positron emission tomography.
155 Citations2002Richard Hargreaves
PET occupancy studies in humans predicted that very high levels of central NK1 receptor occupancy were associated with therapeutically significant antidepressant and antiemetic effects, and future PET imaging studies will focus on quantification ofNK1 receptor expression in depressed patients, both before and after successful treatment with antidepressants.
European Journal of NeuroscienceNeurokinin 1 receptor and relative abundance of the short and long isoforms in the human brain
152 Citations2003Laura Caberlotto, Yasmin L. Hurd +5 more
The anatomical evidence that the NK1 receptors have a strong association with neuronal systems relevant to mood regulation and stress in the human brain is provided, but do not suggest a region‐specific role of the two isoforms in the CNS.
CancerPrevention of cisplatin‐induced acute and delayed emesis by the selective neurokinin‐1 antagonists, L‐758,298 and MK‐869
148 Citations2002Simon Van Belle, M. Lichinitser +14 more
This data indicates that antiemetic therapy with a triple combination of the neurokinin‐1 receptor antagonist MK‐869, a serotonin (5‐HT3) antagonist, and dexamethasone provides enhanced control of cisplatin‐induced emesis compared with standard therapy regimens.
European NeuropsychopharmacologyThe role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development
118 Citations2002Peter S. Talbot
The contribution of human PET and SPECT neuroreceptor occupancy studies to the understanding of drug action in psychiatric illness, and how they can aid the development of new drugs is reviewed.
European Journal of PharmacologyIn vitro and in vivo predictors of the anti-emetic activity of tachykinin NK1 receptor antagonists
117 Citations1997N.M.J. Rupniak, F.D. Tattersall +15 more
It is confirmed that the anti-emetic activity of tachykinin NK1 receptor antagonists is dependent on brain penetration.
Expert Opinion on PharmacotherapyAprepitant – a novel NK1-receptor antagonist
77 Citations2003Lisa Patel, Celeste Lindley
An overview of aprepitant including pharmacokinetics, pharmacology and clinical evidence for its use in CINV is provided and a brief discussion of other possible indications for Aprepitant will also be presented.
NeuropharmacologyBrain uptake and receptor binding of two [11C]labelled selective high affinity NK1-antagonists, GR203040 and GR205171 — PET studies in rhesus monkey
72 Citations2000Mats Bergström, Karl Johan Fasth +6 more
The studies indicated that [11C]GR205171 could be used for the in vivo characterisation of NK1-receptor binding and indicated that the highest specific binding was in the striatum.
Molecular Imaging and BiologySynthesis and characterization of a potent, selective, radiolabeled substance-P antagonist for NK receptor quantitation: ([F]SPA-RQ)
54 Citations2004Olof Solin, Olli Eskola +8 more
SPA-RQ is a potent, high affinity Substance-P antagonist that can be conveniently labeled with high specific activity using [18F]fluoromethylbromide and is a useful tool for noninvasive imaging of central NK1 receptors.
Journal of Pharmacology and Experimental TherapeuticsCorrelation of Neurokinin (NK) 1 Receptor Occupancy in Gerbil Striatum with Behavioral Effects of NK1 Antagonists
51 Citations2002Ruth A. Duffy, Geoffrey B. Varty +2 more
Ex vivo binding studies indicate that increased NK1 receptor occupancy in striatum by NK1 antagonists parallels the inhibition of agonist-mediated GFT.
Drug Metabolism and DispositionBRAIN PENETRATION OF APREPITANT, A SUBSTANCE P RECEPTOR ANTAGONIST, IN FERRETS
49 Citations2003Su-Er W. Huskey, Brian J. Dean +10 more
Analysis of the pharmacokinetics, metabolism, and brain penetration of the neurokinin 1 (NK1) receptor antagonist (substance P receptor antagonist), aprepitant, in ferrets suggested that aprepant, rather than its metabolites, was responsible, primarily, for the antiemetic activity of this compound in the male ferret.
Substance P Receptors
47 Citations1980Michael R. Hanley, Leslie L. Iversen
Substance P is an undecapeptide with powerful spasmogenic activity on smooth muscle originally identified in extracts of equine intestine by von Euler and Gaddum (1931) and later isolated from hypothalamus and characterized by Chang and Leeman (1970) and Chang et al. (1971).
NeuropharmacologyEffects of subchronic treatment with imipramine, zimelidine and alaproclate on regional tissue levels of substance P-and neurokinin a/neurokinin B-like immunoreactivity in the brain and spinal cord of the rat
40 Citations1987Ernst Brodin, Sven Ove Ögren +1 more
Subchronic treatment of rats with inhibitors of the uptake of monoamines induced changes in levels of tachykinin in frontal cortex, periaqueductal grey and spinal cord.